COMP <GO>
KEQU vs ABBV // EV/EBITDA & P/E VALUATION
Kewaunee Scientific Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: KEQU 5
— ABBV 8
▲ EV/EBITDA & P/E VALUATION LEADER: KEQU
LAST: $33.51 (-3.48%) • MKT CAP: $97.0M
valuation
6.3x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KEQU VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KEQU | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.50% | 70.20% | -41.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.70% | 29.00% | -12.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.3x | 33.3x | -27.00 | KEQU | /valuation <GO> |
| Free Cash Flow Yield | 19.20% | 3.47% | +15.73 | KEQU | /fcf-yield <GO> |
| Operating Margin | 5.90% | 24.60% | -18.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 6.90% | -3.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 17.30% | 8.60% | +8.70 | KEQU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 5.33 | -1.96 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | KEQU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.3 | 65.1 | -15.77 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 113.1x | -104.60 | KEQU | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $97.0M | $513.86B | -$513.76B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KEQU REV | ABBV REV | KEQU GROSS % | ABBV GROSS % | KEQU FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $282.0M | $61.16B | 28.5% | 70.2% | $18.6M | $17.82B |
| FY 2024 | $240.5M | $56.33B | 28.6% | 70.0% | $14.8M | $17.83B |
| FY 2023 | $203.8M | $54.32B | — | — | $19.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KEQU // BETA —
ABBV // BETA 1.15